Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can gut microbes hold the key to liver health?

NCT ID NCT06291571

Knowledge-focused Sponsor: University of Aberdeen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

Researchers at the University of Aberdeen are studying how the community of microbes in the gut, known as the gut microbiota, differs in people with liver disease compared to healthy controls. The liver receives blood from the gut, and changes in gut microbes may affect liver function and the immune system. By analyzing stool samples and liver biopsies from 200 participants aged 18 to 70, the team aims to identify which bacteria, fungi, and viruses are present and how the immune system responds. This research could help design new ways to prevent and treat liver disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study succeeds, it could point toward new treatments that target gut microbes to prevent or treat liver disease.
What could go wrong
This is an observational study, so it will not test any treatment directly. The findings may not lead to new therapies, and the results may not apply to all liver disease patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients in clinics and wards in secondary care.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to provide informed consent 2. Definitive diagnosis of specific liver disease utilising clinical, biochemical, and radiological tests 3. Male or female aged between 18-70 years 4. Able to understand written or verbal information in English Exclusion Criteria: 1. Pregnancy and breastfeeding 2. Treatment with antibiotics in the last month 3. Treatment with steroids or immunosuppressive drugs in the last month 4. Regular consumption of over-the-counter prebiotics and probiotics from pharmacies or other retailers in the last month. 5. Known gastrointestinal disease, including but not limited to ulcerative colitis, Crohn's disease, coeliac disease, microscopic colitis, diverticulitis, irritable bowel syndrome 6. Patients diagnosed with cancer who are on chemotherapy, radiotherapy, or immunotherapy within the last 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gut microbiome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gut microbiome Liver diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Medical Sciences

    Aberdeen, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.